1Ziswiler R,Steinmann-Niggli K,Kappele A,et al.Mycophenolic acid:a new approach to the therapy of experimental mesangial proliferative glomerulonephritis.J Am Soc Nephrol,1998,9:2055-2066.
2Tan EM,Cohen AS,Fries JF,et al.The 1982 revised criteria for the classification of systemic lupus erythematosus.Arthritis Rheum,1982,25:1271-1277.
3Fulton B,Markham A.Mycophenolate mofetil:a review of its pharmacodynamic and pharmcokinetic properties and clinical efficacy in renal transplantation.Drug,1996,51:278-298.
4Abduo NI,Sweiman B,Casella SR.Effects of azathioprine therapy on bone marrow-dependent and thymus-dependent cells in man.Clin Exp Immunol,1973,13:55-64.
5US Renal Transplant Mycophenolate Mofetil Study Group.Mycophenolate mofetil in cadaveric renal transplantation.Am J Kidney Dis,1999,34:296-303.
6Dooley MA,Cosio FG,Nachman PH,et al.Mycophenolate mofetil therapy in lupus nephritis:clinical observations.J Am Soc Nephrol,1999,10:833-839.
7Kulper-Geertsma DG,Derksen RH. Newer drugs for the treatment of lupus nephritis. Drugs,2003:63167-180.
8Illei GG,Czirjak L. Novel approaches In the treatment of lupus nephritis. txpert Opln Investig Drugs ,2001,10 : 1117-1130.
9Cameron JS. Lupus nephritis. J Am Soc Nephrol,1999 ,10 :413.
10Allison AC, EuguiEM, Solliner HW. Mycophenolate mofetil (RS-61443) : mechanism of action and effects in transplantation. Transplant Rev, 1993,7 : 129-139.
